Piramal Consumer Healthcare bets on power brands, quick commerce for $200M by 2030
Piramal is pruning its FMCG portfolio to focus on Lacto Calamine, i-pill and new i-choose women's wellness line, leaning on premiumization, influencer marketing and quick commerce (over half of e-commerce sales) to nearly double FY26 revenue of ₹1,274 cr to $200M by 2030.
What happened
Piramal Consumer Healthcare is narrowing focus to power brands, premiumization, influencer marketing and quick commerce (over half of its e-commerce business)
Key facts
- $200 million revenue target by 2030
- ₹1,274 crore FY26 revenue
- 17% segment growth
- 31 new products in FY26 vs 63 in FY23
- 80% new product success rate
- one-third of business from e-commerce
- 200,000 chemist stores active, 450,000 total
- India BPC market $23bn to $40bn by 2030
- OTC market ₹60,000 cr to ₹98,000 cr by 2030
Why this matters
Piramal's portfolio pruning could surface divestiture targets in non-core FMCG SKUs, while the i-choose push into women's wellness flags an active acquirer in OTC personal care adjacencies.
What to watch
- FY27 revenue print — needs ~₹1,550 cr to stay on $200M trajectory
- i-pill market share vs Mankind's Unwanted-72 (currently ~60:40 split)
- New category entries (sexual wellness, intimate care) signaling i-choose ambition
- Piramal Group capital allocation commentary on consumer vertical
- Quick commerce share crossing 60% of e-com — margin compression signal
- Influencer marketing ROI disclosures or pullback
- Track i-choose SKU launches and shelf velocity on Nykaa/Blinkit dashboards monthly
- Benchmark Lacto Calamine vs Cetaphil/Minimalist in derma-adjacent skincare pricing tiers
- Map ad spend ratio (likely 18-22% of sales) and influencer roster expansion
- Watch for D2C acquisitions in women's wellness to plug i-choose gaps
- Monitor q-commerce dependency risk if platforms hike commissions in 2025-26
Also reported by
- Mint — Same time